Pancreatic cancer trials recruiting in Virginia
All Pancreatic cancer trials nationally
66
Recruiting in Virginia
17
Cities with sites
Cities in Virginia
Fairfax 52Charlottesville 11Richmond 10Roanoke 5Norfolk 3Winchester 3Alexandria 2Falls Church 2Leesburg 2Mechanicsville 2Midlothian 2Blacksburg 1
Recruiting trials in Virginia
- A 2-part Phase 1/2 Open-label Trial on ODM-212
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
- A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- A Study of PHN-012 in Patients With Advanced Solid Tumors
- A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
- A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
- Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
- Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
- LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
- Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
- Pancreatic Cancer Early Detection Consortium
- Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
- Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
- Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
- Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors